The cyclin-dependent kinase inhibitor Roughex is involved in mitotic exit in Drosophila

被引:31
|
作者
Foley, E [1 ]
Sprenger, F [1 ]
机构
[1] Univ Cologne, Genet Inst, D-50931 Cologne, Germany
关键词
D O I
10.1016/S0960-9822(01)00050-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Exit from mitosis is a tightly regulated event. This process has been studied in greatest detail in budding yeast, where several activities have been identified that cooperate to downregulate activity of the cyclin-dependent kinase (CDK) Cdc28 and force an exit from mitosis. Cdc28 is inactivated through proteolysis of B-type cyclins by the multisubunit ubiquitin ligase termed the anaphase promoting complex/cyclosome (APC/C) and inhibition by the cyclin-dependent kinase inhibitor (CKI) Sic1. In contrast, the only mechanism known to be essential for CDK inactivation during mitosis in higher eukaryotes is cyclin destruction. Results: We now present evidence that the Drosophila CKI Rougher (Rux) contributes to exit from mitosis, Observations of fixed and living embryos show that metaphase is significantly longer in rux mutants than in wild-type embryos. In addition, Rux overexpression is sufficient to drive cells experimentally arrested in metaphase into interphase. Furthermore, rux mutant embryos are impaired in their ability to overcome a transient metaphase arrest induced by expression of a stable cyclin A. Rux has numerous functional similarities with Sic1. While these proteins share no sequence similarity, we show that Sic1 inhibits mitotic Cdk1-cyclin complexes from Drosophila in vitro and in vivo, Conclusions: Rux inhibits Cdk1-cyclin A kinase activity during metaphase, thereby contributing to exit from mitosis, To our knowledge, this is the first mitotic function ascribed to a CKI in a multicellular organism and indicates the existence of a novel regulatory mechanism for the metaphase to anaphase transition during development.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 50 条
  • [41] Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials
    Senderowicz, AM
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) : 313 - 320
  • [42] The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase
    Kaiser, A
    Nishi, K
    Gorin, FA
    Walsh, DA
    Bradbury, EM
    Schnier, JB
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 386 (02) : 179 - 187
  • [43] SNS-032. Cyclin-dependent kinase inhibitor, Oncolytic.
    Vasiliou, S.
    DRUGS OF THE FUTURE, 2008, 33 (11) : 932 - 937
  • [44] The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics
    Schutte, B
    Nieland, L
    vanEngeland, M
    Henfling, MER
    Meijer, L
    Ramaekers, FCS
    EXPERIMENTAL CELL RESEARCH, 1997, 236 (01) : 4 - 15
  • [45] The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
    Tanaka, Tomohito
    Terai, Yoshito
    Ashihara, Keisuke
    Fujiwara, Satoe
    Tanaka, Yoshimichi
    Sasaki, Hiroshi
    Tsunetoh, Satoshi
    Ohmichi, Masahide
    PLOS ONE, 2017, 12 (05):
  • [46] Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer
    Wang, SD
    McClue, SJ
    Ferguson, JR
    Hull, JD
    Stokes, S
    Parsons, S
    Westwood, R
    Fischer, PM
    TETRAHEDRON-ASYMMETRY, 2001, 12 (20) : 2891 - 2894
  • [47] Purification and crystallization of cyclin-dependent kinase inhibitor p21
    Mayrose, DR
    Nichols, MA
    Yue, XO
    Ke, HM
    PROTEIN SCIENCE, 1996, 5 (09) : 1928 - 1930
  • [48] PRELIMINARY CRYSTALLIZATION OF A CYCLIN-DEPENDENT KINASE INHIBITOR: P18.
    Jarchow, Shannon
    Ke, Hengming
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 1996, 52 : C235 - C235
  • [49] Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
    Toogood, PL
    Harvey, PJ
    Repine, JT
    Sheehan, DJ
    VanderWel, SN
    Zhou, HR
    Keller, PR
    McNamara, DJ
    Sherry, D
    Zhu, T
    Brodfuehrer, J
    Choi, C
    Barvian, MR
    Fry, DW
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) : 2388 - 2406
  • [50] Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities
    Villerbu, N
    Gaben, AM
    Redeuilh, G
    Mester, J
    INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (06) : 761 - 769